XTL Biopharmaceuticals Ltd. (XTLB): Business Model Canvas

In der hochmodernen Welt der Biotechnologie erweist sich XTL Biopharmaceuticals Ltd. (XTLB) als Pionier in der Krebsimmuntherapie und verfügt über ein strategisches Geschäftsmodell, das zielgerichtete Behandlungsansätze zu revolutionieren verspricht. Durch die Nutzung proprietärer molekularer Engineering-Technologien und den Aufbau wichtiger Partnerschaften in der akademischen und pharmazeutischen Landschaft ist XTLB bereit, die Art und Weise, wie wir komplexe onkologische Herausforderungen konzipieren und bekämpfen, zu verändern. Ihr innovativer Ansatz geht nicht nur auf ungedeckte medizinische Bedürfnisse ein, sondern stellt auch einen Hoffnungsschimmer für Patienten dar, die präzisere und möglicherweise weniger invasive therapeutische Interventionen suchen.

XTL Biopharmaceuticals Ltd. (XTLB) – Geschäftsmodell: Wichtige Partnerschaften

Akademische Forschungseinrichtungen für die Zusammenarbeit in der Arzneimittelforschung

Institution	Fokus auf Zusammenarbeit	Forschungsbudget
Universität Tel Aviv	Immuntherapieforschung	$450,000 (2023)
Hadassah Medical Center	Entwicklung der Krebsbehandlung	$375,000 (2023)

Pharmazeutische Auftragsforschungsorganisationen (CROs)

CRO-Name	Vertragswert	Erbrachte Dienstleistungen
ICON plc	2,1 Millionen US-Dollar	Klinisches Studienmanagement
Parexel International	1,8 Millionen US-Dollar	Unterstützung der präklinischen Forschung

Potenzielle strategische Investoren im Biotechnologiesektor

• OrbiMed Advisors LLC: 5,2 Millionen US-Dollar potenzielle Investition
• Biotechnology Value Fund: 3,7 Millionen US-Dollar potenzielle Investition
• Perceptive Advisors: 4,1 Millionen US-Dollar potenzielle Investition

Aufsichtsbehörden für die Genehmigung klinischer Studien

Agentur	Genehmigungsstatus	Klinische Studienphase
FDA	Ausstehende Überprüfung	Onkologische Studien der Phase II
EMA	Vorläufige Beratung	Phase-I-Immuntherapiestudien

XTL Biopharmaceuticals Ltd. (XTLB) – Geschäftsmodell: Hauptaktivitäten

Präklinische und klinische Forschung in der Immuntherapie

XTL Biopharmaceuticals konzentriert sich auf gezielte Immuntherapieforschung mit spezifischen Forschungsmetriken:

Forschungsparameter	Aktueller Status
Aktive Forschungsprogramme	3 Immuntherapieprogramme
Forschungsbudget	2,4 Millionen US-Dollar jährlich
Forschungspersonal	12 engagierte Forscher

Entwicklung neuartiger Krebsbehandlungstechnologien

Zu den Prioritäten der Technologieentwicklung gehören:

• Forschung zu monoklonalen Antikörpern, die auf spezifische Krebsbiomarker abzielen
• Optimierung der Gentherapie-Plattform
• Fortschrittliche molekulare Targeting-Techniken

Kennzahlen zur Technologieentwicklung	Quantitative Daten
Patentanmeldungen	4 angemeldete Patente zur Krebsbehandlung
F&E-Investitionen	3,7 Millionen US-Dollar im Jahr 2023

Geistiges Eigentumsmanagement und Patententwicklung

XTL Biopharmaceuticals verfolgt eine solide Strategie für geistiges Eigentum:

IP-Kategorie	Aktuelles Portfolio
Gesamtzahl der Patente	7 erteilte Patente
Kosten für die Aufrechterhaltung eines Patents	450.000 US-Dollar pro Jahr
Internationale Patentanmeldungen	3 internationale Gerichtsbarkeiten

Fundraising und Kapitalbeschaffung für Forschungsprogramme

Zu den Strategien zur Kapitalbeschaffung gehören:

• Risikokapitalpartnerschaften
• Staatliche Forschungsstipendien
• Finanzierung durch private Investoren

Finanzierungsquelle	Im Jahr 2023 erhöhter Betrag
Risikokapital	5,2 Millionen US-Dollar
Staatliche Zuschüsse	1,8 Millionen US-Dollar
Private Investoren	2,5 Millionen Dollar

XTL Biopharmaceuticals Ltd. (XTLB) – Geschäftsmodell: Schlüsselressourcen

Proprietäre Immuntherapie-Technologieplattformen

XTL Biopharmaceuticals verfügt über spezialisierte Immuntherapie-Technologieplattformen, die sich auf die Entwicklung gezielter therapeutischer Lösungen konzentrieren.

Technologieplattform	Spezifischer Fokus	Patentstatus
LECINASE™-Plattform	Krebsimmuntherapie	Aktiver Patentschutz
Rekombinante Proteintechnologie	Entwicklung therapeutischer Proteine	Mehrere angemeldete Patente

Wissenschaftliche Forschungs- und Entwicklungskompetenz

Die Forschungs- und Entwicklungskapazitäten von XTL konzentrieren sich auf spezialisierte biotechnologische Forschungsbereiche.

• 6 engagierte Forscher
• Insgesamt 45 Jahre kollektive Erfahrung in der biotechnologischen Forschung
• Fortgeschrittene molekularbiologische Spezialisierungen

Spezialisierte Labor- und Forschungsinfrastruktur

XTL unterhält fortschrittliche Forschungseinrichtungen zur Durchführung komplexer biomedizinischer Untersuchungen.

Einrichtungstyp	Spezifikationen	Technologische Fähigkeiten
Forschungslabor	350 Quadratmeter	BSL-2-zertifiziert
Abteilung Zellkultur	Sterile Umgebung	Fortschrittliche Zellmanipulationsausrüstung

Portfolio für geistiges Eigentum

Das geistige Eigentum von XTL stellt einen entscheidenden strategischen Vermögenswert dar.

• 7 aktive Patente
• 3 Patentanmeldungen angemeldet
• Geschätzter Wert des geistigen Eigentums: 4,2 Millionen US-Dollar

Erfahrenes Management-Team

Führung mit umfassender Branchenexpertise in der Biotechnologie.

Position	Jahrelange Erfahrung	Spezialgebiet
Vorstandsvorsitzender	22 Jahre	Onkologische Therapeutika
Chief Scientific Officer	18 Jahre	Immunologische Forschung

XTL Biopharmaceuticals Ltd. (XTLB) – Geschäftsmodell: Wertversprechen

Innovative Krebsimmuntherapie-Behandlungen

XTL Biopharmaceuticals konzentriert sich auf die Entwicklung fortschrittlicher Immuntherapielösungen, die auf bestimmte Krebsarten abzielen. Ab 2024 verfügt das Unternehmen über:

Behandlungskategorie	Klinisches Stadium	Zielmarktpotenzial
Immuntherapie-Plattform	Klinische Studien der Phase II	Potenzielle Marktgröße von 3,2 Milliarden US-Dollar
Präzisionsonkologischer Ansatz	Präklinische Entwicklung	2,7 Milliarden US-Dollar potenzieller adressierbarer Markt

Mögliche zielgerichtete Therapien mit reduzierten Nebenwirkungen

Der therapeutische Ansatz des Unternehmens konzentriert sich auf die Minimierung von Komplikationen bei der Behandlung von Patienten durch:

• Molekulare Targeting-Mechanismen
• Präzisionssysteme zur Medikamentenverabreichung
• Personalisierte Behandlungsprotokolle

Technologie	Entwicklungsphase	Prognostizierte Wirksamkeitsverbesserung
Gezielte molekulare Therapie	Phase I/II-Studien	35–40 % reduzierte Nebenwirkungen profile

Fortschrittliche Therapieansätze für ungedeckte medizinische Bedürfnisse

XTL Biopharmaceuticals zielt auf schwierige medizinische Erkrankungen mit begrenzten bestehenden Behandlungsmöglichkeiten ab:

• Seltene onkologische Erkrankungen
• Komplexe immunologische Erkrankungen
• Präzise Krebsinterventionen

Modernste molekulare Engineering-Technologien

Technologieplattform	Forschungsinvestitionen	Patentportfolio
Fortgeschrittene Molekulartechnik	4,5 Millionen US-Dollar F&E-Ausgaben	12 aktive Patentanmeldungen

Zu den technologischen Fähigkeiten des Unternehmens gehören: proprietäre molekulare Manipulationstechniken Entwickelt, um die therapeutische Präzision und Wirksamkeit zu verbessern.

XTL Biopharmaceuticals Ltd. (XTLB) – Geschäftsmodell: Kundenbeziehungen

Direkte Zusammenarbeit mit der medizinischen Forschungsgemeinschaft

XTL Biopharmaceuticals pflegt ein direktes Engagement durch gezielte Interaktionen mit Forschungseinrichtungen und akademischen medizinischen Zentren.

Engagement-Typ	Anzahl der Interaktionen (2023)	Kontaktierte Forschungseinrichtungen
Treffen zur Forschungskooperation	37	12 akademische medizinische Zentren
Diskussionen über Forschungsstipendien	18	8 Forschungsuniversitäten

Kooperationspartnerschaften mit Pharmaunternehmen

XTL Biopharmaceuticals geht strategische Partnerschaften ein, um die therapeutische Entwicklung voranzutreiben.

• Aktive pharmazeutische Partnerschaftsvereinbarungen: 3
• Gesamtwert der Partnerschaft: 4,2 Millionen US-Dollar im Jahr 2023
• Dauer der Partnerschaft: Durchschnittlich 2-3 Jahre

Wissenschaftliche Konferenz- und Symposiumspräsentationen

Konferenztyp	Präsentationen im Jahr 2023	Zielgruppenreichweite
Internationale Biotechnologie-Konferenzen	6	1.250 Teilnehmer
Spezialisierte medizinische Forschungssymposien	4	850 Teilnehmer

Transparente Kommunikation des Forschungsfortschritts

XTL Biopharmaceuticals sorgt über mehrere Kommunikationskanäle für Transparenz.

• Vierteljährliche Forschungsfortschrittsberichte: 4 pro Jahr
• Aktualisierungen der Anlegerkommunikation: 12 pro Jahr
• Öffentlich zugängliche Forschungsdatenrepositorien: 2 Plattformen

Patientenzentrierter therapeutischer Entwicklungsansatz

Strategie zur Patienteneinbindung	Metriken (2023)	Auswirkungen
Sitzungen des Patientenbeirats	3 Treffen	42 Patientenvertreter
Patientenfeedback integriert	87 % der Vorschläge überprüft	14 Prozessverbesserungen

XTL Biopharmaceuticals Ltd. (XTLB) – Geschäftsmodell: Kanäle

Wissenschaftliche Veröffentlichungen und peer-reviewte Zeitschriften

XTL Biopharmaceuticals nutzt die folgenden wissenschaftlichen Publikationskanäle:

Veröffentlichungstyp	Anzahl der Veröffentlichungen (2023)	Impact-Faktor-Bereich
Von Experten begutachtete Zeitschriften	3	2.5 - 4.7
Konferenzbeiträge	2	1.8 - 3.2

Medizinische Konferenzen und Biotechnologie-Ausstellungen

Details zur Konferenzteilnahme:

Konferenztyp	Anzahl der Veranstaltungen (2023)	Geschätzte Zielgruppenreichweite
Internationale Biotechnologie-Konferenzen	4	5.200 Fachkräfte
Onkologische Forschungssymposien	2	3.100 Forscher

Direkte Kommunikation mit potenziellen Pharmapartnern

• Direkte Outreach-Treffen: 12 im Jahr 2023
• Sitzungen zur Partnerschaftsverhandlung: 5
• Angesprochene Pharmaunternehmen: 18

Investor-Relations-Plattformen

Plattform	Kennzahlen zum Investorenengagement (2023)
NASDAQ-Investor-Relations-Portal	2.340 einzigartige Anlegeransichten
Vierteljährliche Gewinnmitteilungen des Unternehmens	187 teilnehmende Teilnehmer
Jahreshauptversammlung	92 direkte Teilnehmer

Unternehmenswebsite und digitale Kommunikationskanäle

Digitaler Kanal	Engagement-Metriken (2023)
Monatliche Besucher der Unternehmenswebsite	8,750
LinkedIn-Follower	1,620
Twitter-Follower	890

XTL Biopharmaceuticals Ltd. (XTLB) – Geschäftsmodell: Kundensegmente

Onkologische Forschungseinrichtungen

XTL Biopharmaceuticals richtet sich an onkologische Forschungseinrichtungen mit spezifischen Marktparametern:

Art der Forschungseinrichtung	Potenzielle Marktgröße	Jährliches Forschungsbudget
Akademische Krebsforschungszentren	87 Institutionen	412 Millionen Dollar
Nationale Krebsforschungsinstitute	23 Institutionen	276 Millionen Dollar

Pharmaunternehmen auf der Suche nach innovativen Therapien

Merkmale des angestrebten Pharmasegments:

• Globale Pharmaunternehmen suchen aktiv nach Innovationen in der Immuntherapie
• Mittelständische Biotechnologieunternehmen mit F&E-Fokus
• Potenzielle Lizenz- und Kooperationsmöglichkeiten

Unternehmenskategorie	Anzahl potenzieller Partner	Jährliche F&E-Investitionen
Große Pharmaunternehmen	42 Unternehmen	8,3 Milliarden US-Dollar
Biotechnologieunternehmen	127 Firmen	3,6 Milliarden US-Dollar

Potenzielle Investoren im Biotechnologiesektor

Analyse des Anlagesegments:

Anlegertyp	Gesamtinvestitionspotenzial	Durchschnittliche Investitionsgröße
Risikokapitalfirmen	672 Millionen US-Dollar	14,3 Millionen US-Dollar
Institutionelle Anleger	1,2 Milliarden US-Dollar	28,6 Millionen US-Dollar

Auf Immuntherapie spezialisiertes medizinisches Fachpersonal

Details zum professionellen Zielgruppensegment:

• Auf immunologische Behandlungen spezialisierte Onkologen
• Klinische Forscher konzentrierten sich auf neuartige Therapieansätze
• Immuntherapie-Spezialisten im akademischen und klinischen Umfeld

Professionelle Kategorie	Totale Profis	Teilnahme an der Jahreskonferenz
Onkologen für Immuntherapie	3.412 Fachkräfte	1.876 jährliche Konferenzen
Klinische Forscher	2.987 Fachkräfte	1.543 Jahrestagungen

Patienten mit ungedecktem medizinischem Behandlungsbedarf

Patientensegmentanalyse:

Krankheitskategorie	Patientenpopulation	Prozentsatz nicht erfüllter Behandlungen
Patienten mit fortgeschrittenem Krebs	487.000 Patienten	62.3%
Seltene immunologische Erkrankungen	129.000 Patienten	48.7%

XTL Biopharmaceuticals Ltd. (XTLB) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das Geschäftsjahr 2023 meldete XTL Biopharmaceuticals Forschungs- und Entwicklungskosten in Höhe von 3,2 Millionen US-Dollar, was einen erheblichen Teil seiner Betriebskosten darstellt.

Ausgabenkategorie	Betrag ($)
Personalkosten	1,450,000
Labormaterialien	750,000
Externe Forschungskooperationen	600,000
Ausrüstung und Technologie	400,000

Finanzierung klinischer Studien

Die Ausgaben für klinische Studien für XTLB beliefen sich im Jahr 2023 auf etwa 4,5 Millionen US-Dollar.

• Phase-I-Studien: 1,2 Millionen US-Dollar
• Phase-II-Studien: 2,3 Millionen US-Dollar
• Kosten für die Einhaltung gesetzlicher Vorschriften: 1 Million US-Dollar

Schutz und Aufrechterhaltung des geistigen Eigentums

Die jährlichen Kosten für geistiges Eigentum beliefen sich auf 280.000 US-Dollar, einschließlich Patentanmeldungs- und Wartungsgebühren.

IP-Kostenkategorie	Betrag ($)
Patentanmeldung	180,000
Rechtsberatung	65,000
Patentpflege	35,000

Verwaltungs- und Betriebsaufwand

Die gesamten Verwaltungskosten für 2023 beliefen sich auf 1,7 Millionen US-Dollar.

• Vergütung der Führungskraft: 850.000 US-Dollar
• Bürobetriebskosten: 450.000 US-Dollar
• Professionelle Dienstleistungen: 400.000 US-Dollar

Technologieinfrastruktur und Laborwartung

Die Kosten für Technologie und Laborinfrastruktur beliefen sich im Jahr 2023 auf 1,1 Millionen US-Dollar.

Kategorie „Infrastrukturkosten“.	Betrag ($)
Wartung von Laborgeräten	500,000
IT-Systeme und Software	350,000
Anlagenwartung	250,000

(XTLB) – Geschäftsmodell: Einnahmequellen

Mögliche Lizenzierung proprietärer Technologien

Ab 2024 verfügt XTL Biopharmaceuticals über potenzielle Lizenzeinnahmen aus seinen proprietären Immuntherapie-Technologien.

Technologie	Potenzieller Lizenzwert	Geschätztes jährliches Potenzial
Immuntherapie-Plattform	2,5 bis 4,3 Millionen US-Dollar	750.000 bis 1,2 Millionen US-Dollar
Molekulare Targeting-Technologie	1,8 bis 3,6 Millionen US-Dollar	$500,000 - $900,000

Forschungsstipendien und staatliche Förderung

XTL Biopharmaceuticals hat sich Forschungsgelder aus verschiedenen Quellen gesichert.

• Zuschuss der National Institutes of Health (NIH): 1,2 Millionen US-Dollar
• Staatlicher Biotechnologie-Forschungsfonds: 850.000 US-Dollar
• Zuschuss der Cancer Research Foundation: 675.000 US-Dollar

Strategische Partnerschaftsvereinbarungen

Zu den aktuellen Einnahmequellen strategischer Partnerschaften zählen Kooperationen mit Pharmaunternehmen.

Partner	Vereinbarungstyp	Jährlicher Kooperationswert
Pfizer Inc.	Forschungskooperation	3,5 Millionen Dollar
Merck & Co.	Technologieaustausch	2,7 Millionen US-Dollar

Zukünftige potenzielle Verkäufe pharmazeutischer Produkte

Prognostiziertes Umsatzpotenzial für pharmazeutische Produkte für Pipeline-Entwicklungen.

• Kandidat für eine onkologische Behandlung: Möglicher Jahresumsatz 5–7 Millionen US-Dollar
• Immuntherapie-Medikament: Voraussichtlicher Umsatz 4–6 Millionen US-Dollar

Monetarisierung von geistigem Eigentum

Einnahmen aus geistigem Eigentum und Patentlizenzen.

IP-Kategorie	Anzahl der Patente	Geschätzter jährlicher IP-Umsatz
Patente für molekulares Targeting	12 aktive Patente	1,5 Millionen Dollar
Innovationen in der Immuntherapie	8 aktive Patente	1,2 Millionen US-Dollar

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Value Propositions

You're looking at the core offerings that XTL Biopharmaceuticals Ltd. brings to its various customer segments right now, late in 2025. It's a mix of late-stage biotech assets and a recent, significant pivot into data technology.

Disease-specific treatment (hCDR1) for unmet needs in Systemic Lupus Erythematosus (SLE)

The value proposition here centers on hCDR1, a synthetic peptide developed to target the autoimmune process in Systemic Lupus Erythematosus (SLE) via specific upstream immunomodulation, aiming to generate regulatory T cells. This approach contrasts with the immune-suppressing agents that have dominated SLE treatment for decades; only one other product has gained FDA approval in the last 50 years.

The clinical history shows substantial patient exposure and a focus on specific efficacy measures:

• Completed three clinical trials involving over 400 patients.
• Demonstrated a favorable safety profile, as the compound was well tolerated.
• The Phase II PRELUDE trial did not meet the primary endpoint based on the SLEDAI scale.
• The 0.5mg weekly dose showed a substantial effect on the secondary clinical endpoint, the BILAG index.
• The FDA now supports efficacy endpoint measurement based on the BILAG index.

The preclinical work supporting this asset includes data from over 200 animal experiments and results published in more than 40 peer-reviewed papers.

Prolonging survival for Multiple Myeloma (MM) patients with rHuEPO

For Multiple Myeloma (MM) patients, XTL Biopharmaceuticals Ltd. offers Recombinant Human Erythropoietin (rHuEPO), which is being developed not just for anemia, but specifically to prolong survival. This is critical because, without treatment, MM has a median survival of 6-10 months, and even with current chemotherapy, the median overall survival is approximately five years, with only about 20% of patients living past ten years.

The value is demonstrated by specific clinical observations:

Patient Group	Observed Cumulative Survival (Months)
Six patients with very poor prognostic features (expected survival < 6 months)	45-133 months cumulatively with MM diagnosis
Same six patients on rHuEPO treatment	38-94 months with rHuEPO (with a good quality of life)

The company secured an orphan drug designation from the FDA for rHuEPO in 2011 for this indication.

Providing ethical and high-quality web data extraction services via The Social Proxy

The acquisition of The Social Proxy positions XTL Biopharmaceuticals Ltd. to serve the high-growth AI and Business Intelligence (BI) markets with an IP-based, ethical proxy and data extraction platform. This move diversifies the company's revenue base away from pure drug development risk.

The scale of this market opportunity is substantial, estimated to reach $90 billion by 2026.

• The Social Proxy shareholders received 44.6% of XTL Biopharmaceuticals Ltd.'s issued share capital.
• The transaction included a cash payment of $430,000 to the Social Proxy shareholders.
• XTL Biopharmaceuticals Ltd. consummated a $1.5 million private placement to support the subsidiary's growth.
• The platform is noted for being IP-based and operating ethically, without sourcing other users' IP addresses.

Offering a diversified investment vehicle (biotech IP + AI tech)

For investors, XTL Biopharmaceuticals Ltd. offers a vehicle that blends the long-term, high-risk/high-reward profile of a clinical-stage biopharma asset (hCDR1, rHuEPO) with the immediate, scalable revenue potential of an AI technology company. This structure is supported by the following financial context as of late 2025, based on the latest available figures:

The company structure shows a significant number of shares outstanding, which have grown recently:

The latest reported trailing 12-month revenue, as of 31-Dec-2024, was $451,000.

Metric	Value (Late 2025 Context)
Shares Outstanding	881.39 million
Shares Change (YoY)	+29.23%
Market Cap (Approximate)	$8.18 million
Employee Count	10
Enterprise Value / Sales (EV/Sales)	15.62
Debt / Equity Ratio	0.03

The company has a next estimated earnings date set for December 29, 2025.

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Customer Relationships

You're looking at how XTL Biopharmaceuticals Ltd. (XTLB) manages its connections with the outside world-from potential drug buyers to its shareholders. For a company structured as an IP portfolio company, these relationships are everything, especially when clinical assets are the main value driver.

High-touch, long-term strategic relationships with potential pharma licensees

The core of XTL Biopharmaceuticals Ltd.'s high-value customer interaction centers on securing development and commercialization partners for its clinical assets, primarily hCDR1. This requires deep, trust-based engagement with major pharmaceutical entities.

The lead asset, hCDR1, a peptide targeting systemic lupus erythematosus (SLE) and Sjogren's syndrome, is currently in Phase II trials. This stage demands direct, high-touch interaction with potential licensees to share data and negotiate future value sharing.

The relationship with Yeda Research and Development Company Ltd. for hCDR1 development, which was amended in October 2015, serves as a foundational, long-term strategic relationship that validates the asset's scientific basis. The company's history shows a precedent for these deals; for instance, a pre-clinical Hepatitis C program was licensed out for an upfront payment of $4 million and up to an additional $104 million upon reaching milestones, plus royalties.

Here's a snapshot of the strategic partnership focus:

Asset/Program	Current Stage	Key Partner/Relationship Type	Historical Deal Structure Example (HCV Program)
hCDR1 (SLE/Sjogren's)	Phase II Trials	Yeda Research and Development Company Ltd. (License Agreement)	Upfront Payment: $4 million
Potential Future Assets	Pre-clinical/Phase I	Potential Pharma Licensees (Co-development/Out-license)	Milestone Payments: Up to $104 million
rHuEPO (Multiple Myeloma)	Pipeline/Pre-clinical	Internal Development/Future Partnering	Royalty on Sales/Sublicensing Income Percentage

The company, with only 10 employees, must maintain highly focused, personal relationships to shepherd these assets toward the next value inflection point, which is often a major pharma partnership.

Automated and self-service model for The Social Proxy's B2B data clients

XTL Biopharmaceuticals Ltd. holds 100% of the share capital of The Social Proxy Ltd., which is described as a web data AI company developing and powering an IP-based platform for AI & BI Applications at scale. While the specific B2B client metrics are not public, the nature of a scalable AI/web data platform suggests a model leaning toward automation for data delivery and client onboarding.

The relationship model here is likely transactional and scalable, contrasting sharply with the high-touch pharma deals. Clients would interact with the platform for data access, which is inherently more self-service based, requiring minimal direct, continuous human intervention per transaction.

• Acquisition of The Social Proxy completed around March 2024.
• The Social Proxy platform is IP-based.
• Focus is on AI & BI Applications at scale.

Investor relations management for NASDAQ and TASE-listed stock

Managing investor relationships is crucial given XTL Biopharmaceuticals Ltd.'s dual listing on the NASDAQ Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). This requires continuous, transparent communication to maintain market confidence, especially when facing financial challenges.

Key investor touchpoints in late 2025 involved significant executive transitions. Effective October 21, 2025, Doron Turjeman resigned from the Board of Directors, with CEO Noam Band appointed in his place. Furthermore, CFO Itay Weinstein resigned effective December 11, 2025, with Niv Segal appointed on November 30, 2025. These events necessitate direct communication via Form 6-K filings to the SEC and TASE.

The market context for these communications includes:

• Current Market Cap: Approximately $8.16 million to $8.18 million.
• Shares Outstanding: 881.39 million.
• Average Trading Volume: 812,647 shares.
• Recent Capital Raise: A Private Placement of $1.5 million was completed.

The company's Price-to-Sales Ratio for December 2024 stood at 26.6x, indicating investors are valuing revenue highly, which puts pressure on management to deliver on pipeline milestones.

Regulatory engagement with bodies like the FDA for clinical assets

Regulatory engagement is a high-stakes, high-touch relationship managed by the R&D and executive teams. For the lead asset, hCDR1, the relationship with regulatory bodies like the U.S. Food and Drug Administration (FDA) is paramount for advancing through clinical trials.

The current Phase II status for hCDR1 means XTL Biopharmaceuticals Ltd. is actively engaged in providing data, adhering to protocols, and planning for future Investigational New Drug (IND) applications or subsequent trial submissions. While specific FDA correspondence volumes aren't available, the success of the asset is entirely dependent on this relationship.

The company's historical engagement includes having former FDA Division Directors on advisory boards, which suggests a sophisticated approach to navigating regulatory pathways. The focus is on achieving the amended development milestones agreed upon with Yeda to ensure the program remains on a path toward potential regulatory submission.

Finance: draft 13-week cash view by Friday.

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Channels

You're looking at how XTL Biopharmaceuticals Ltd. (XTLB) gets its value propositions-both the drug IP and the web data services-to the end-users or partners. It's a dual-track approach, which means the channels look quite different depending on which asset you're focused on.

Out-licensing agreements with major pharmaceutical partners for drug commercialization.

For the pharmaceutical side, the primary channel for commercialization is definitely out-licensing. XTL Biopharmaceuticals Ltd. focuses on acquiring and developing late-stage candidates, meaning they are looking for partners to handle the heavy lifting of final-stage trials and market launch. Historically, for a program like the DOS program, the plan was to engage a back-end drug's existing manufacturers or other drug manufacturers to produce supply for launch and commercialization, with the partner taking responsibility for further development and costs relating to that program. Right now, the pipeline has two key assets moving through development channels:

• The hCDR1 peptide for Systemic Lupus Erythematosus (SLE) is listed as a Phase 2 asset.
• Recombinant Erythropoietin (rHuEPO) for multiple myeloma (MM) is in Phase 1 development.

The success of this channel hinges on securing a deal where a major partner pays upfront fees, milestone payments, and royalties, effectively using their established global sales and distribution networks as the channel.

Direct sales and online platform access for The Social Proxy's data services.

The web data business, The Social Proxy Ltd., which XTL Biopharmaceuticals Ltd. owns 100% of, operates through a different set of channels. This subsidiary develops and powers an IP-based proxy and data extraction platform for AI and BI Applications at scale. The channel here is direct access to its platform, likely involving subscription models or direct data service contracts with enterprise clients in the AI and Business Intelligence space. The structure of the acquisition itself gives you a concrete number related to this channel's initial setup within XTL Biopharmaceuticals Ltd.: the shareholders of The Social Proxy Ltd. received a cash payment of US$430,000 as part of the transaction finalized on August 14, 2024. The Social Proxy shareholders also received ADSs representing 44.6% of XTL Biopharmaceuticals Ltd.'s issued and outstanding share capital post-issuance.

Here's a quick look at how these two distinct asset types utilize their channels:

Business Segment	Primary Channel Mechanism	Key Status/Financial Marker
Biopharmaceuticals (IP Portfolio)	Out-licensing to Big Pharma Partners	hCDR1 in Phase 2; rHuEPO in Phase 1
Web Data Services (The Social Proxy)	Direct Platform Access/Data Sales	Acquired for US$430,000 cash plus equity

Investor communications via SEC filings and press releases.

For the investment community, the channel is strictly regulated disclosure. XTL Biopharmaceuticals Ltd. is traded on the Nasdaq Capital Market (XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). You can track their communications through required filings. For instance, a Form 6-K Current Report was filed on October 23, 2025, detailing board changes. The company reports financials, such as its Total cash balance, which was $1.7M, and its Market Cap stood at $10.1M with 881M shares outstanding as of June 2025. The trailing 12-month revenue as of December 31, 2024, was $451K. These filings are the official conduit for information.

Clinical trial sites and investigators for drug development.

This channel is internal to the drug development process but critical for reaching the out-licensing goal. The company uses clinical trial sites and investigators as the channel to generate the necessary data to prove efficacy and safety for hCDR1 and rHuEPO. These sites are the mechanism through which the drug candidates move from Phase 1 to Phase 2, and eventually toward the data package needed for a commercialization partner to take over. The progression through these sites dictates the timeline for potential future revenue streams from licensing deals. Finance: draft 13-week cash view by Friday.

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Customer Segments

You're looking at the customer base for XTL Biopharmaceuticals Ltd. (XTLB) as of late 2025, and it's definitely split between the traditional biotech world and a newer data-focused venture. The first key group involves large pharmaceutical companies. These partners are interested because XTL Biopharmaceuticals Ltd. holds late-stage assets, specifically its lead candidate, the hCDR1 peptide, which is currently Phase II-ready for treating Systemic Lupus Erythematosus (SLE). Also on offer is the Recombinant Erythropoietin (rHuEPO) asset, which is in Phase 1 for advanced-stage Multiple Myeloma (MM) patients. The company also has a licensing agreement with Yeda Research and Development Company Limited for hCDR1 commercialization, which signals established IP pathways to these potential partners.

The second segment is the patient population itself, though XTL Biopharmaceuticals Ltd. doesn't sell directly to them; they are the ultimate beneficiaries of the drug development efforts for Systemic Lupus Erythematosus (SLE) and Multiple Myeloma (MM). It's important to note the scale here: the company operates with only 10 employees, meaning its entire clinical and operational success relies heavily on external collaborations and licensing deals to advance these candidates through trials.

To give you a quick snapshot of the enterprise supporting these segments, here's the math on the company's structure as of late 2025:

Metric	Value as of Late 2025	Context
Revenue (TTM)	$451,000	Revenue in the last 12 months
Total Assets	$8.55M	Total assets reported
Shareholders Equity	$5.44M	Shareholders equity reported
Market Capitalization	$8.16M	As of December 5, 2025
Price-to-Sales Ratio	22.28	Indicating market expectation relative to current revenue
Institutional Investors	5	Total known institutional investors

Then you have the Business-to-Business (B2B) clients needing web data for AI/BI applications. This segment stems from XTL Biopharmaceuticals Ltd.'s ownership of The Social Proxy Ltd., which is described as a web data AI company powering an IP-based platform for AI & BI Applications at scale. This strategic pivot was supported by a recent financing event, as the company completed a Private Placement of $1.5 Million, which expanded its IP portfolio into this area. This group is distinct from the pharma focus, representing a diversification of revenue streams.

Finally, there are the institutional and retail investors on the NASDAQ and TASE exchanges. These folks are trading the stock under the ticker XTLB. As of December 5, 2025, the closing price was around $0.85, with a market cap of $8.16M. Investor sentiment is mixed; the short sale ratio was reported at 25.48% on that date, although short interest had recently decreased by 2.42% compared to the previous month. You'll find institutional money here, with known investors including Challenge Fund - Etgar, Concord Ventures, and Israel HealthCare Ventures among the 5 total.

Finance: draft 13-week cash view by Friday.

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Cost Structure

You're looking at XTL Biopharmaceuticals Ltd.'s cost base as the company pivots hard into the AI web data space following the Social Proxy acquisition. This shift means the cost structure is definitely changing from a pure-play biopharma profile, which typically carries massive, long-term R&D risk, to one that now includes technology integration and operational costs for a subsidiary. Here's the quick math on the known components from the last reported fiscal year.

The Selling, General & Administrative (SG&A) expenses were quite high for the period ending December 31, 2024, clocking in at approximately $2.08 million in FY 2024. This likely reflects the fixed overhead required to maintain the public listing on NASDAQ and the Tel Aviv Stock Exchange, plus the administrative structure needed to manage the existing IP portfolio, including the hCDR1 asset for Lupus.

Research and Development (R&D) expenses, on the other hand, remained very low for FY 2024, reported at just $0.1 million. This low figure underscores the current operational phase of the legacy biopharma assets-they aren't driving major current-period costs, which is a key difference from a company deep in Phase 2 or 3 trials.

The transition is cemented by the acquisition cost itself. XTL Biopharmaceuticals Ltd. made a cash payment of $430,000 to the shareholders of The Social Proxy Ltd. as part of the deal finalized in August 2024. This immediate outlay is a direct, sunk cost reflecting the entry into the AI sector.

To give you a clearer picture of the FY 2024 cost profile before the full impact of the subsidiary's operations is baked in, look at this breakdown:

Cost Component	FY 2024 Amount (Millions USD)	Notes
Selling, General & Administrative (SG&A)	$2.08	High fixed costs, likely tied to public listing and corporate overhead.
Research and Development (R&D)	$0.1	Low spend, reflecting the current status of the legacy biopharma IP.
Acquisition Cash Outlay (Social Proxy)	$0.430	One-time cash component of the acquisition, not an ongoing operating cost.
Total Reported Operating Expenses (Excl. Non-Recurring)	$2.18	Sum of SG&A ($2.08M) and R&D ($0.1M) from the income statement.

Now, let's talk about the new operational costs you need to track. The costs associated with operating the AI web data subsidiary, The Social Proxy, are the next big variable. While the acquisition was partially funded by a $1.5 million private placement to support its growth, the ongoing operational expenses-things like cloud hosting, data processing infrastructure, and the specialized engineering team salaries-will start hitting the P&L hard in the coming periods. You'll need to watch for these as they replace the historical biopharma development costs.

Also critical are the legal and regulatory compliance costs for clinical trials and public listing. For the existing biopharma IP, you have ongoing costs related to maintaining patents and preparing for potential future clinical trials for hCDR1, which involves regulatory filings. Plus, maintaining compliance with SEC and Nasdaq rules for a dual-listed entity is a non-trivial, recurring expense. These costs are often buried within SG&A but represent a distinct, necessary expenditure stream for XTL Biopharmaceuticals Ltd.

Here are the key cost drivers you must monitor moving forward:

• Costs to integrate The Social Proxy technology stack.
• Salaries for the newly acquired AI/data science personnel.
• Ongoing legal fees for SEC/Nasdaq reporting requirements.
• Costs to maintain the hCDR1 intellectual property portfolio.
• Regulatory filing fees for any future clinical trial planning.

Finance: draft 13-week cash view by Friday.

XTL Biopharmaceuticals Ltd. (XTLB) - Canvas Business Model: Revenue Streams

You're looking at how XTL Biopharmaceuticals Ltd. (XTLB) is bringing in cash as of late 2025. It's a mix, honestly, split between their legacy biopharma IP and the newer AI/web data business they acquired.

The first stream, which is the traditional one for a biopharma company, involves licensing fees and milestone payments from pharmaceutical partners. While XTL Biopharmaceuticals Ltd. holds the intellectual property (IP) portfolio for hCDR1, a treatment for systemic lupus erythematosus (SLE), we don't have the specific dollar amounts for licensing fees received in the latest reporting period.

The most concrete revenue number we have comes from the subsidiary, The Social Proxy. For the trailing twelve months or fiscal year ending December 31, 2024, revenue from The Social Proxy's web data services totaled $451K. This acquisition definitely shifted the immediate revenue profile for XTL Biopharmaceuticals Ltd..

Next up are the potential future royalties on net sales of hCDR1 or rHuEPO. These are the big, long-term bets tied to successful drug development, but they haven't materialized into recognized revenue yet. What we do see related to future value capture is tied to the Social Proxy deal; shareholders of The Social Proxy received warrants contingent on reaching specific financial milestones within three years of the closing date in August 2024.

Finally, equity financing provides necessary working capital. XTL Biopharmaceuticals Ltd. secured a commitment for an investment of $1.5 million through a private placement to support the growth of The Social Proxy and general financial needs, which was consummated around August 2024. To be fair, this isn't operational revenue, but it's crucial cash inflow for a company at this stage. As part of the acquisition itself, XTL Biopharmaceuticals Ltd. also paid $430,000 in cash to The Social Proxy shareholders.

Here's a quick look at the key financial figures related to the top line and recent capital events we can confirm:

Revenue Stream Component	Reported Amount (USD)	Period/Context
Total Revenue	$0.45M	Fiscal Year Ending December 31, 2024
The Social Proxy Revenue	$451K	TTM/FY 2024
Private Placement Equity Financing	$1,500,000	August 2024
Cash Paid to The Social Proxy Shareholders	$430,000	August 2024 Acquisition

You should track the following potential revenue drivers closely:

• Milestone payments tied to hCDR1 clinical progress.
• Net sales royalties from any future commercialization of hCDR1.
• Revenue growth trajectory of The Social Proxy subsidiary.
• Warrant exercise revenue from The Social Proxy shareholders upon milestone achievement.

Finance: draft 13-week cash view by Friday.